Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cougar Biotechnology has reported positive data from the Phase I dose ranging trial of company's prostate cancer drug candidate CB7630 or abiraterone acetate.
Subscribe to our email newsletter
Of the 33 patients who were enrolled in the study, four patients had prostate specific antigen (PSA) only disease, 27 patients had bone metastases and three patients had visceral disease. Nineteen of 33 patients (58%) had received prior treatment with ketoconazole.
Overall, 27 of the 30 evaluable patients (90%) experienced a decline in PSA levels while receiving CB7630, with 16 of 30 patients (53%) experiencing a greater than 50% decline in PSA levels. Of the 11 patients in the trial who had not received prior ketoconazole treatment, six patients (55%) experienced a greater than 50% decline in PSA levels as a result of treatment with CB7630. Additionally, 10 (53%) of the 19 patients who had previously received ketoconazole experienced a 50% or greater decline in PSA while receiving CB7630. The median time to progression in the patients who had previously received ketoconazole was 21 weeks.
Alan Auerbach, CEO and president of Cougar Biotechnology, said: “We greatly look forward to the continued development of CB7630 in both the second line hormone therapy and second line chemotherapy settings.”